Search

Your search keyword '"Markus Magerl"' showing total 217 results

Search Constraints

Start Over You searched for: Author "Markus Magerl" Remove constraint Author: "Markus Magerl"
217 results on '"Markus Magerl"'

Search Results

3. Advent of oral medications for the treatment of hereditary angioedema

4. The real life experience goes on: update after 4 years on the first cohort treated with lanadelumab at our center

5. The current situation of hereditary angioedema patients in Germany: results of an online survey

6. A multicenter chart review of patient characteristics, treatment, and outcomes in hereditary angioedema: unmet need for more effective long-term prophylaxis

7. Could it be hereditary angioedema?—Perspectives from different medical specialties

8. Sensitivity to change and minimal clinically important difference of the angioedema control test

9. Patient‐physician interactions in hereditary angioedema—Key learnings from the coronavirus disease 2019 pandemic

10. Attenuated androgen discontinuation in patients with hereditary angioedema: a commented case series

11. Case report: Recurrent angioedema: Diagnosing the rare and the frequent

12. HAE patient self-sampling for biomarker establishment

13. Searching for Genetic Biomarkers for Hereditary Angioedema Due to C1-Inhibitor Deficiency (C1-INH-HAE)

14. Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study

15. A Germany-wide survey study on the patient journey of patients with hereditary angioedema

16. A novel deep intronic SERPING1 variant as a cause of hereditary angioedema due to C1-inhibitor deficiency

17. The international WAO/EAACI guideline for the management of hereditary angioedema – The 2021 revision and update

18. Chronic urticaria patients are interested in apps to monitor their disease activity and control: A UCARE CURICT analysis

19. How are patients with chronic urticaria interested in using information and communication technologies to guide their healthcare? A UCARE study

20. Correction to: Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study

21. The usage, quality and relevance of information and communications technologies in patients with chronic urticaria: A UCARE study

22. Improvement in diagnostic delays over time in patients with hereditary angioedema: findings from the Icatibant Outcome Survey

23. Epidemiology of Bradykinin-mediated angioedema: a systematic investigation of epidemiological studies

24. An open-label study to evaluate the long-term safety and efficacy of lanadelumab for prevention of attacks in hereditary angioedema: design of the HELP study extension

25. Abstracts from the 10th C1-inhibitor deficiency workshop

27. Efficacy and Safety of an Intravenous C1-Inhibitor Concentrate for Long-Term Prophylaxis in Hereditary angioedema

28. Expert Perspectives on Hereditary Angioedema: Key Areas for Advancements in Care across the Patient Journey

29. WAO Guideline for the Management of Hereditary Angioedema

30. Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

31. CRUSE – What the first 100 days have taught us

33. An investigational oral plasma kallikrein inhibitor for on-demand treatment of hereditary angioedema : a two-part, randomised, double-blind, placebo-controlled, crossover phase 2 trial

34. Garadacimab, a Factor XIIa Inhibitor for Hereditary Angioedema Prevention (VANGUARD Study)

35. Patients with hereditary angioedema and their treatment patterns in Germany: a Delphi consensus study

37. The characteristics and impact of pruritus in adult dermatology patients: A prospective, cross-sectional study

38. Impact of lanadelumab on health‐related quality of life in patients with hereditary angioedema in the HELP study

39. A novel deep intronic SERPING1 variant as a cause of hereditary angioedema due to C1-inhibitor deficiency

41. Development of the Angioedema Control Test—A patient‐reported outcome measure that assesses disease control in patients with recurrent angioedema

42. International Consensus on the Use of Genetics in the Management of Hereditary Angioedema

43. The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria

44. Efficacy and Safety of Subcutaneous Garadacimab for the Prophylaxis of Hereditary Angioedema Attacks in Adults and Adolescent Patients with HAE: Results from a Multicenter, Placebo-Controlled Phase 3 Trial

46. Efficacy And Safety Of Bradykinin B2 Receptor Inhibition With Oral PHVS416 In Treating Hereditary Angioedema Attacks: Results Of RAPIDe-1 Phase 2 Trial

47. Consensus on treatment goals in hereditary angioedema:a global Delphi initiative

48. HAE patient self-sampling for biomarker establishment

49. Attenuated androgen discontinuation in patients with hereditary angioedema: a commented case series

50. Mitigating Disparity in Health-care Resources Between Countries for Management of Hereditary Angioedema

Catalog

Books, media, physical & digital resources